Psoriasis Clinical Trial
Official title:
A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Verified date | May 2024 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy. The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.
Status | Active, not recruiting |
Enrollment | 160 |
Est. completion date | February 22, 2027 |
Est. primary completion date | February 22, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: Subject must satisfy the following criteria to be enrolled in the study: 1. Subject is male or female 6 to 17 years of age, inclusive, at the time the informed consent document is signed by the legal guardian. 2. Subject must have a weight of = 20 kg. 3. Subjects must have an age and sex specific BMI value no lower in range than the 5th percentile on the Centers for Disease Control (CDC) growth chart for children and adolescents. 4. Subject must have completed Week 52 (Apremilast Extension Phase) of Study CC-10004-PPSO-003. 5. Subject is able to sign an assent with a legal guardian/s who understand/s and voluntarily sign/s an informed consent prior to any study-related assessments/procedures being conducted. 6. Subject is willing and able to adhere to the study visit schedule and other protocol requirements. 7. All female subjects of childbearing potential (FCBP) must either practice abstinence from heterosexual contact or use one of the approved contraceptive options as described below while on apremilast and for at least 28 days after administration of the last dose of apremilast. For the purpose of this study, a female subject is considered of childbearing potential if she is = 12 years old or has reached menarche, whichever occurred first. At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding abstinence or contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy. Females of childbearing potential must have a negative pregnancy test at each visit. All FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below: Option 1: Any one of the following effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide. NOTE: Option 2 may not be acceptable as a contraception option in all countries per local guidelines/regulations. Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: 1. Subject has a condition, including the presence of laboratory abnormalities, or psychiatric illness, that would place the subject at unacceptable risk if he/she were to participate in the study. 2. Subject has a condition that confounds the ability to interpret data from the study. 3. Subject has evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments. 4. Subject is pregnant or breastfeeding. 5. Subject has guttate, erythrodermic, or pustular psoriasis. 6. Subject has active tuberculosis (TB) or a history of incompletely treated TB. 7. Subject answers "Yes" to any question on the Columbia-Suicide Severity Rating Scale at Visit 16 of study CC-10004-PPSO-003. 8. Subject plans concurrent use of the following therapies that may have a possible effect on psoriasis. 1. Conventional systemic therapy for psoriasis (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters) 2. Biologic therapy: i. Etanercept (or biosimilar) treatment ii. Adalimumab (or biosimilar) treatment iii. Other TNF or interleukin (IL)-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) iv. Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) c) Use of any investigational drug other than apremilast 9. Subject has prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources. 10. Children in Care: a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. |
Country | Name | City | State |
---|---|---|---|
Belgium | Centre Hospitalier Universitaire Saint Pierre | Brussels | |
Belgium | Cliniques Universitaires Saint Luc | Brussels | |
Belgium | Universitair Ziekenhuis Gent | Gent | |
Canada | Stollery Childrens Hospital | Edmonton | Alberta |
Canada | Karma Clinical Trials | St. John's | Newfoundland and Labrador |
Canada | AvantDerm | Toronto | Ontario |
Canada | Winnipeg Clinic Dermatology Research | Winnipeg | Manitoba |
Czechia | Synexus Czech sro | Praha | |
Czechia | Fakultni nemocnice Kralovske Vinohrady | Praha 10 | |
France | Cabinet du Docteur Ruer-Mulard Mireille | Martigues | |
France | Centre Hospitalier Universitaire de Toulouse - Hopital Larrey | Toulouse | |
Israel | Soroka University Medical Center | Bear Sheva | |
Italy | Azienda Ospedaliero Universitaria Di Cagliari | Cagliari | |
Italy | Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico | Milano | |
Italy | Azienda Ospedaliera di Padova | Padova | |
Russian Federation | Altai State Medical University | Barnaul | |
Russian Federation | Chelyabinsk Regional Clinical Skin and Venereal Dispensary | Chelyabinsk | |
Russian Federation | Ural Scientific Research Institute of Dermatovenereology and Immunopathology | Ekaterinburg | |
Russian Federation | Republican Clinical Dermatology and Venerology Dispensary | Kazan | |
Russian Federation | Clinical Dispensary of Dermatology and Venereology of Krasnodar Territory of the Ministry of Health | Krasnodar | |
Russian Federation | Moscow Scientific Practical Center of Dermatology Venerology and Cosmetology | Moscow | |
Russian Federation | National Medical Research Center for Children Health | Moscow | |
Russian Federation | State Scientific Center for Dermatovenereology and Cosmetology | Moscow | |
Russian Federation | LLC Medical Center Zdorovaya Semiya | Novosibirsk | |
Russian Federation | LLC PiterKlinika | Saint Petersburg | |
Russian Federation | Pierre Wolkenshtein Skin Diseases Clinic LLC | Saint Petersburg | |
Russian Federation | Saint Petersburg State Pediatric Medical University | Saint Petersburg | |
Russian Federation | Bashkiria State Medical University | Ufa | |
Russian Federation | Yarosavl State Medical Academy | Yaroslavl | |
Spain | General University Hospital of Alicante | Alicante | |
Spain | Hopsital Germans Trias I Pujol | Badalona | |
Spain | Hospital Sant Joan de Deu | Esplugues de Llobregat | Cataluña |
Spain | Hospital 12 de Octubre | Madrid | |
Spain | Hospital General Universitario Gregorio Maranon | Madrid | |
Spain | Hospital Infantil Universitario Nino Jesus | Madrid | |
Spain | Hospital La Paz | Madrid | |
Spain | Hospital Marques de Valdecilla | Santander | |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Wright State Physicians | Fairborn | Ohio |
United States | Johnson Dermatology Clinic | Fort Smith | Arkansas |
United States | Dawes Fretzin Dermatology Group Inc | Indianapolis | Indiana |
United States | First OC Dermatology | Irvine | California |
United States | Solutions Through Advanced Research Inc | Jacksonville | Florida |
United States | Skin Care Physicians of Georgia | Macon | Georgia |
United States | University of Wisconsin Hospital and Clinics | Madison | Wisconsin |
United States | Ciocca Dermatology | Miami | Florida |
United States | Stanford University School of Medicine | Palo Alto | California |
United States | Phoenix Childrens Hospital | Phoenix | Arizona |
United States | Driscoll Childrens Hospital | San Antonio | Texas |
United States | California Dermatology Institute | Thousand Oaks | California |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Belgium, Canada, Czechia, France, Israel, Italy, Russian Federation, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events (AEs) | An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. | Up to approximately 4 years | |
Primary | Columbia-Suicide Severity Rating Scale (C-SSRS) | Questionnaire to monitor depression, suicidal thoughts and behavior | Collected at each study visit throughout the life of the study - up to 4 years | |
Primary | Weight of patients treated with Apremilast | Body weight in kg | Collected at each study visit throughout the life of the study - up to 4 years | |
Primary | Mean body mass index of the patient treated with Apremilast | BMI (combined outcome of weight and height in the form of kg/m^2) | Collected at each study visit throughout the life of the study - up to 4 years | |
Primary | Height patients treated with Apremilast | Height (inches or centimeters) will be collected for all pediatric subjects and descriptively summarized | Collected at each study visit throughout the life of the study - up to 4 years | |
Primary | Assessment of sexual maturity | Sexual maturation, assessed by Tanner staging system, will be conducted for all pediatric subjects and descriptively summarized | Collected every 52 weeks throughout the life of the study - up to 4 years | |
Secondary | Static Physician Global Assessment (sPGA) | is the assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. | Collected at each study visit throughout the life of the study - up to 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |